Gate Bioscience

Executive Summary

Gate Bioscience is pioneering a novel therapeutic modality called Molecular Gates, which are small molecule drugs designed to selectively eliminate harmful extracellular proteins at their source—inside the cell—before they can cause disease. Founded in 2021 and based in South San Francisco, the company aims to address a wide range of pathologies driven by secreted proteins, including fibrosis, oncology, and inflammatory diseases. By targeting proteins early in their synthesis and secretion pathway, Molecular Gates offer the potential for improved selectivity and reduced systemic side effects compared to traditional extracellular neutralization approaches. As a private, early-stage biotechnology company, Gate Bioscience has not yet disclosed specific pipeline candidates or clinical timelines, but its platform technology has attracted interest for its paradigm-shifting potential in protein elimination. The company's progress will depend on advancing lead programs toward candidate selection and initial preclinical validation.

Upcoming Catalysts (preview)

• Q3 2026Lead Program Candidate Nomination70% success
• Q1 2027IND-Enabling Studies Initiation50% success
• Q2 2026New Partnership or Funding Round Announcement60% success